ID   P85B_HUMAN              Reviewed;         728 AA.
AC   O00459; Q5EAT5; Q9UPH9;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 2.
DT   10-MAY-2017, entry version 176.
DE   RecName: Full=Phosphatidylinositol 3-kinase regulatory subunit beta;
DE            Short=PI3-kinase regulatory subunit beta;
DE            Short=PI3K regulatory subunit beta;
DE            Short=PtdIns-3-kinase regulatory subunit beta;
DE   AltName: Full=Phosphatidylinositol 3-kinase 85 kDa regulatory subunit beta;
DE            Short=PI3-kinase subunit p85-beta;
DE            Short=PtdIns-3-kinase regulatory subunit p85-beta;
GN   Name=PIK3R2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-234 AND PRO-313.
RX   PubMed=1314371;
RA   Volinia S., Patracchini P., Otsu M., Hiles I., Gout I., Calzolari E.,
RA   Bernardi F., Rooke L., Waterfield M.D.;
RT   "Chromosomal localization of human p85 alpha, a subunit of
RT   phosphatidylinositol 3-kinase, and its homologue p85 beta.";
RL   Oncogene 7:789-793(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ARG-234 AND PRO-313.
RX   PubMed=9582025; DOI=10.1038/sj.onc.1201695;
RA   Janssen J.W.G., Schleithhoff L., Bartram C.R., Schulz A.S.;
RT   "An oncogenic fusion product of the phosphatidylinositol 3-kinase
RT   p85beta subunit and HUMORF8, a putative deubiquitinating enzyme.";
RL   Oncogene 16:1767-1772(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-234 AND
RP   PRO-313.
RC   TISSUE=Brain, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH AXL.
RX   PubMed=9178760; DOI=10.1038/sj.onc.1201123;
RA   Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R.,
RA   Ullrich A., Bartram C.R., Janssen J.W.;
RT   "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is
RT   mediated mainly by a multi-substrate docking-site.";
RL   Oncogene 14:2619-2631(1997).
RN   [6]
RP   INTERACTION WITH FLT1.
RX   PubMed=9600074; DOI=10.1006/bbrc.1998.8578;
RA   Igarashi K., Isohara T., Kato T., Shigeta K., Yamano T., Uno I.;
RT   "Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2.";
RL   Biochem. Biophys. Res. Commun. 246:95-99(1998).
RN   [7]
RP   INTERACTION WITH FLT4.
RX   PubMed=15102829; DOI=10.1074/jbc.M314015200;
RA   Wang J.F., Zhang X., Groopman J.E.;
RT   "Activation of vascular endothelial growth factor receptor-3 and its
RT   downstream signaling promote cell survival under oxidative stress.";
RL   J. Biol. Chem. 279:27088-27097(2004).
RN   [8]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPRJ.
RX   PubMed=18348712; DOI=10.1042/BJ20071317;
RA   Tsuboi N., Utsunomiya T., Roberts R.L., Ito H., Takahashi K., Noda M.,
RA   Takahashi T.;
RT   "The tyrosine phosphatase CD148 interacts with the p85 regulatory
RT   subunit of phosphoinositide 3-kinase.";
RL   Biochem. J. 413:193-200(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-605, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-464, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-464, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   FUNCTION, INTERACTION WITH FBXL2 AND PTPN13, PHOSPHORYLATION AT
RP   TYR-655, DEPHOSPHORYLATION AT TYR-655 BY PTPN13, UBIQUITINATION,
RP   DOMAIN, AND MUTAGENESIS OF GLN-651; ARG-652 AND TYR-655.
RX   PubMed=23604317; DOI=10.1038/ncb2731;
RA   Kuchay S., Duan S., Schenkein E., Peschiaroli A., Saraf A.,
RA   Florens L., Washburn M.P., Pagano M.;
RT   "FBXL2- and PTPL1-mediated degradation of p110-free p85beta regulatory
RT   subunit controls the PI(3)K signalling cascade.";
RL   Nat. Cell Biol. 15:472-480(2013).
RN   [16]
RP   INVOLVEMENT IN MPPH1, AND VARIANT MPPH1 PRO-401.
RX   PubMed=23745724; DOI=10.1111/cge.12188;
RA   Nakamura K., Kato M., Tohyama J., Shiohama T., Hayasaka K.,
RA   Nishiyama K., Kodera H., Nakashima M., Tsurusaki Y., Miyake N.,
RA   Matsumoto N., Saitsu H.;
RT   "AKT3 and PIK3R2 mutations in two patients with megalencephaly-related
RT   syndromes: MCAP and MPPH.";
RL   Clin. Genet. 85:396-398(2014).
RN   [17]
RP   INVOLVEMENT IN MPPH1, AND VARIANT MPPH1 ARG-373.
RX   PubMed=22729224; DOI=10.1038/ng.2331;
RA   Riviere J.B., Mirzaa G.M., O'Roak B.J., Beddaoui M., Alcantara D.,
RA   Conway R.L., St-Onge J., Schwartzentruber J.A., Gripp K.W.,
RA   Nikkel S.M., Worthylake T., Sullivan C.T., Ward T.R., Butler H.E.,
RA   Kramer N.A., Albrecht B., Armour C.M., Armstrong L., Caluseriu O.,
RA   Cytrynbaum C., Drolet B.A., Innes A.M., Lauzon J.L., Lin A.E.,
RA   Mancini G.M., Meschino W.S., Reggin J.D., Saggar A.K.,
RA   Lerman-Sagie T., Uyanik G., Weksberg R., Zirn B., Beaulieu C.L.,
RA   Majewski J., Bulman D.E., O'Driscoll M., Shendure J., Graham J.M. Jr.,
RA   Boycott K.M., Dobyns W.B.;
RT   "De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA
RT   cause a spectrum of related megalencephaly syndromes.";
RL   Nat. Genet. 44:934-940(2012).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [19]
RP   VARIANTS MPPH1 ARG-373 AND GLU-376.
RX   PubMed=26520804; DOI=10.1016/S1474-4422(15)00278-1;
RA   Mirzaa G.M., Conti V., Timms A.E., Smyser C.D., Ahmed S., Carter M.,
RA   Barnett S., Hufnagel R.B., Goldstein A., Narumi-Kishimoto Y., Olds C.,
RA   Collins S., Johnston K., Deleuze J.F., Nitschke P., Friend K.,
RA   Harris C., Goetsch A., Martin B., Boyle E.A., Parrini E., Mei D.,
RA   Tattini L., Slavotinek A., Blair E., Barnett C., Shendure J.,
RA   Chelly J., Dobyns W.B., Guerrini R.;
RT   "Characterisation of mutations of the phosphoinositide-3-kinase
RT   regulatory subunit, PIK3R2, in perisylvian polymicrogyria: a next-
RT   generation sequencing study.";
RL   Lancet Neurol. 14:1182-1195(2015).
RN   [20]
RP   VARIANT MPPH1 HIS-557.
RX   PubMed=26860062; DOI=10.1038/ejhg.2016.7;
RA   Terrone G., Voisin N., Abdullah Alfaiz A., Cappuccio G., Vitiello G.,
RA   Guex N., D'Amico A., James Barkovich A., Brunetti-Pierri N.,
RA   Del Giudice E., Reymond A.;
RT   "De novo PIK3R2 variant causes polymicrogyria, corpus callosum
RT   hyperplasia and focal cortical dysplasia.";
RL   Eur. J. Hum. Genet. 24:1359-1362(2016).
CC   -!- FUNCTION: Regulatory subunit of phosphoinositide-3-kinase (PI3K),
CC       a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol
CC       4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-
CC       trisphosphate (PIP3). PIP3 plays a key role by recruiting PH
CC       domain-containing proteins to the membrane, including AKT1 and
CC       PDPK1, activating signaling cascades involved in cell growth,
CC       survival, proliferation, motility and morphology. Binds to
CC       activated (phosphorylated) protein-tyrosine kinases, through its
CC       SH2 domain, and acts as an adapter, mediating the association of
CC       the p110 catalytic unit to the plasma membrane. Indirectly
CC       regulates autophagy (PubMed:23604317). Promotes nuclear
CC       translocation of XBP1 isoform 2 in a ER stress- and/or insulin-
CC       dependent manner during metabolic overloading in the liver and
CC       hence plays a role in glucose tolerance improvement (By
CC       similarity). {ECO:0000250|UniProtKB:O08908,
CC       ECO:0000269|PubMed:23604317}.
CC   -!- SUBUNIT: Heterodimer of a regulatory subunit PIK3R2 and a p110
CC       catalytic subunit (PIK3CA, PIK3CB or PIK3CD) (PubMed:23604317).
CC       Interacts with AXL (PubMed:9178760). Interacts with FLT1
CC       (tyrosine-phosphorylated) and FLT4 (tyrosine-phosphorylated)
CC       (PubMed:9600074, PubMed:15102829). Interacts with NYAP1, NYAP2 and
CC       MYO16 (By similarity). Interacts with FBXL2; PIK3R2 is a substrate
CC       of the SCF(FBXL2) complex (PubMed:23604317). Interacts with
CC       PTPN13; dephosphorylates PIK3R2 (PubMed:23604317). Interacts with
CC       XBP1 isoform 2; the interaction is direct and induces
CC       translocation of XBP1 isoform 2 into the nucleus in a ER stress-
CC       and/or insulin-dependent but PI3K-independent manner (By
CC       similarity). Interacts with PIK3R1; the interaction is dissociated
CC       in an insulin-dependent manner (By similarity).
CC       {ECO:0000250|UniProtKB:O08908, ECO:0000269|PubMed:15102829,
CC       ECO:0000269|PubMed:23604317, ECO:0000269|PubMed:9178760,
CC       ECO:0000269|PubMed:9600074}.
CC   -!- INTERACTION:
CC       P10275:AR; NbExp=14; IntAct=EBI-346930, EBI-608057;
CC       P22681:CBL; NbExp=4; IntAct=EBI-346930, EBI-518228;
CC       Q8WWB3:DYDC1; NbExp=3; IntAct=EBI-346930, EBI-740680;
CC       P00533:EGFR; NbExp=3; IntAct=EBI-346930, EBI-297353;
CC       P04626:ERBB2; NbExp=6; IntAct=EBI-346930, EBI-641062;
CC       P21860:ERBB3; NbExp=16; IntAct=EBI-346930, EBI-720706;
CC       Q13480:GAB1; NbExp=23; IntAct=EBI-346930, EBI-517684;
CC       Q08379:GOLGA2; NbExp=3; IntAct=EBI-346930, EBI-618309;
CC       P62993:GRB2; NbExp=4; IntAct=EBI-346930, EBI-401755;
CC       P42858:HTT; NbExp=6; IntAct=EBI-346930, EBI-466029;
CC       Q9UKT9:IKZF3; NbExp=3; IntAct=EBI-346930, EBI-747204;
CC       P10721:KIT; NbExp=19; IntAct=EBI-346930, EBI-1379503;
CC       P19012:KRT15; NbExp=3; IntAct=EBI-346930, EBI-739566;
CC       P35900:KRT20; NbExp=3; IntAct=EBI-346930, EBI-742094;
CC       O76015:KRT38; NbExp=3; IntAct=EBI-346930, EBI-1047263;
CC       P08581:MET; NbExp=11; IntAct=EBI-346930, EBI-1039152;
CC       Q96HT8:MRFAP1L1; NbExp=4; IntAct=EBI-346930, EBI-748896;
CC       P03496:NS (xeno); NbExp=13; IntAct=EBI-346930, EBI-2547442;
CC       P42338:PIK3CB; NbExp=3; IntAct=EBI-346930, EBI-2609540;
CC       Q6NUQ1:RINT1; NbExp=3; IntAct=EBI-346930, EBI-726876;
CC       P36406:TRIM23; NbExp=3; IntAct=EBI-346930, EBI-740098;
CC   -!- DOMAIN: The SH2 2 domain is required for interaction with FBXL2
CC       and PTPN13. {ECO:0000269|PubMed:23604317}.
CC   -!- PTM: Phosphorylated in response to signaling from activated
CC       receptor-type protein kinases (PubMed:19690332, PubMed:20068231).
CC       Dephosphorylated by PTPRJ (PubMed:18348712). Dephosphorylated at
CC       Tyr-655 by PTPN13. Phosphorylation of Tyr-655 impairs while its
CC       dephosphorylation promotes interaction with FBXL2 and SCF(FBXL2)-
CC       mediated polyubiquitination (PubMed:23604317).
CC       {ECO:0000269|PubMed:18348712, ECO:0000269|PubMed:23604317}.
CC   -!- PTM: Ubiquitinated. Polyubiquitination by the SCF(FBXL2) complex
CC       probably promotes proteasomal degradation of PIK3R2.
CC       {ECO:0000303|PubMed:23604317}.
CC   -!- DISEASE: Megalencephaly-polymicrogyria-polydactyly-hydrocephalus
CC       syndrome 1 (MPPH1) [MIM:603387]: A syndrome characterized by
CC       megalencephaly, hydrocephalus, and polymicrogyria; polydactyly may
CC       also be seen. There is considerable phenotypic similarity between
CC       this disorder and the megalencephaly-capillary malformation
CC       syndrome. {ECO:0000269|PubMed:22729224,
CC       ECO:0000269|PubMed:23745724, ECO:0000269|PubMed:26520804,
CC       ECO:0000269|PubMed:26860062}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the PI3K p85 subunit family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X80907; CAA56868.1; -; mRNA.
DR   EMBL; AC007192; AAD22671.1; -; Genomic_DNA.
DR   EMBL; BC070082; AAH70082.1; -; mRNA.
DR   EMBL; BC090249; AAH90249.1; -; mRNA.
DR   CCDS; CCDS12371.1; -.
DR   PIR; H59435; H59435.
DR   RefSeq; NP_005018.1; NM_005027.3.
DR   UniGene; Hs.371344; -.
DR   PDB; 2KT1; NMR; -; A=1-80.
DR   PDB; 2XS6; X-ray; 2.09 A; A=108-298.
DR   PDB; 3MTT; X-ray; 3.30 A; A=433-610.
DR   PDB; 3O5Z; X-ray; 2.01 A; A/B=1-85.
DR   PDBsum; 2KT1; -.
DR   PDBsum; 2XS6; -.
DR   PDBsum; 3MTT; -.
DR   PDBsum; 3O5Z; -.
DR   ProteinModelPortal; O00459; -.
DR   SMR; O00459; -.
DR   BioGrid; 111314; 117.
DR   DIP; DIP-31811N; -.
DR   IntAct; O00459; 70.
DR   MINT; MINT-1210047; -.
DR   STRING; 9606.ENSP00000471914; -.
DR   BindingDB; O00459; -.
DR   ChEMBL; CHEMBL3559703; -.
DR   DrugBank; DB01064; Isoprenaline.
DR   DrugBank; DB05210; SF1126.
DR   iPTMnet; O00459; -.
DR   PhosphoSitePlus; O00459; -.
DR   EPD; O00459; -.
DR   MaxQB; O00459; -.
DR   PaxDb; O00459; -.
DR   PeptideAtlas; O00459; -.
DR   PRIDE; O00459; -.
DR   Ensembl; ENST00000222254; ENSP00000222254; ENSG00000105647.
DR   GeneID; 5296; -.
DR   KEGG; hsa:5296; -.
DR   UCSC; uc002nia.3; human.
DR   CTD; 5296; -.
DR   DisGeNET; 5296; -.
DR   GeneCards; ENSG00000268173; -.
DR   GeneCards; PIK3R2; -.
DR   HGNC; HGNC:8980; PIK3R2.
DR   HPA; HPA069291; -.
DR   MalaCards; PIK3R2; -.
DR   MIM; 603157; gene.
DR   MIM; 603387; phenotype.
DR   neXtProt; NX_O00459; -.
DR   OpenTargets; ENSG00000105647; -.
DR   OpenTargets; ENSG00000268173; -.
DR   Orphanet; 83473; Megalencephaly - polymicrogyria - postaxial polydactyly - hydrocephalus.
DR   PharmGKB; PA33313; -.
DR   eggNOG; KOG4637; Eukaryota.
DR   eggNOG; ENOG410XP6R; LUCA.
DR   GeneTree; ENSGT00390000010431; -.
DR   HOGENOM; HOG000008438; -.
DR   HOVERGEN; HBG082100; -.
DR   InParanoid; O00459; -.
DR   KO; K02649; -.
DR   OMA; HYKHTSL; -.
DR   OrthoDB; EOG091G0C3Z; -.
DR   PhylomeDB; O00459; -.
DR   TreeFam; TF102033; -.
DR   BioCyc; MetaCyc:ENSG00000105647-MONOMER; -.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1266695; Interleukin-7 signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-194840; Rho GTPase cycle.
DR   Reactome; R-HSA-198203; PI3K/AKT activation.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-210993; Tie2 Signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-373753; Nephrin interactions.
DR   Reactome; R-HSA-388841; Costimulation by the CD28 family.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-512988; Interleukin-3, 5 and GM-CSF signaling.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   SignaLink; O00459; -.
DR   SIGNOR; O00459; -.
DR   ChiTaRS; PIK3R2; human.
DR   EvolutionaryTrace; O00459; -.
DR   GeneWiki; PIK3R2; -.
DR   GenomeRNAi; 5296; -.
DR   PRO; PR:O00459; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000105647; -.
DR   CleanEx; HS_PIK3R2; -.
DR   ExpressionAtlas; O00459; baseline and differential.
DR   Genevisible; O00459; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; IBA:GO_Central.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; TAS:Reactome.
DR   GO; GO:0046935; F:1-phosphatidylinositol-3-kinase regulator activity; IBA:GO_Central.
DR   GO; GO:0005096; F:GTPase activator activity; TAS:Reactome.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0001784; F:phosphotyrosine binding; IPI:CAFA.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:UniProtKB.
DR   GO; GO:0001678; P:cellular glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046854; P:phosphatidylinositol phosphorylation; IBA:GO_Central.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:2001275; P:positive regulation of glucose import in response to insulin stimulus; ISS:AgBase.
DR   GO; GO:0042993; P:positive regulation of transcription factor import into nucleus; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0010506; P:regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0043551; P:regulation of phosphatidylinositol 3-kinase activity; IBA:GO_Central.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; ISS:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 3.30.505.10; -; 2.
DR   InterPro; IPR032498; PI3K_P85_iSH2.
DR   InterPro; IPR001720; PI3kinase_P85.
DR   InterPro; IPR008936; Rho_GTPase_activation_prot.
DR   InterPro; IPR000198; RhoGAP_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   PANTHER; PTHR10155; PTHR10155; 1.
DR   Pfam; PF16454; PI3K_P85_iSH2; 1.
DR   Pfam; PF00620; RhoGAP; 1.
DR   Pfam; PF00017; SH2; 2.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00324; RhoGAP; 1.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF48350; SSF48350; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   PROSITE; PS50238; RHOGAP; 1.
DR   PROSITE; PS50001; SH2; 2.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disease mutation; Phosphoprotein;
KW   Polymorphism; Protein transport; Reference proteome; Repeat;
KW   SH2 domain; SH3 domain; Stress response; Transport; Ubl conjugation.
FT   CHAIN         1    728       Phosphatidylinositol 3-kinase regulatory
FT                                subunit beta.
FT                                /FTId=PRO_0000080763.
FT   DOMAIN        4     80       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      109    295       Rho-GAP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00172}.
FT   DOMAIN      330    425       SH2 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      622    716       SH2 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   MOD_RES     464    464       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     605    605       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     655    655       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:23604317}.
FT   VARIANT     234    234       S -> R (in dbSNP:rs2241088).
FT                                {ECO:0000269|PubMed:1314371,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:9582025}.
FT                                /FTId=VAR_030679.
FT   VARIANT     313    313       S -> P (in dbSNP:rs1011320).
FT                                {ECO:0000269|PubMed:1314371,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:9582025}.
FT                                /FTId=VAR_030680.
FT   VARIANT     373    373       G -> R (in MPPH1; dbSNP:rs587776934).
FT                                {ECO:0000269|PubMed:22729224,
FT                                ECO:0000269|PubMed:26520804}.
FT                                /FTId=VAR_069262.
FT   VARIANT     376    376       K -> E (in MPPH1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26520804}.
FT                                /FTId=VAR_075556.
FT   VARIANT     401    401       L -> P (in MPPH1; dbSNP:rs587777624).
FT                                {ECO:0000269|PubMed:23745724}.
FT                                /FTId=VAR_075683.
FT   VARIANT     557    557       D -> H (in MPPH1; dbSNP:rs372272045).
FT                                {ECO:0000269|PubMed:26860062}.
FT                                /FTId=VAR_075684.
FT   MUTAGEN     651    651       Q->A: Loss of interaction with FBXL2 and
FT                                increased half-life; when associated with
FT                                A-652. {ECO:0000269|PubMed:23604317}.
FT   MUTAGEN     652    652       R->A: Loss of interaction with FBXL2 and
FT                                increased half-life; when associated with
FT                                A-651. {ECO:0000269|PubMed:23604317}.
FT   MUTAGEN     655    655       Y->A: Stabilized interaction with FBXL2
FT                                and decreased half-life.
FT                                {ECO:0000269|PubMed:23604317}.
FT   STRAND        5     11       {ECO:0000244|PDB:3O5Z}.
FT   STRAND       30     34       {ECO:0000244|PDB:3O5Z}.
FT   HELIX        35     40       {ECO:0000244|PDB:3O5Z}.
FT   HELIX        47     49       {ECO:0000244|PDB:3O5Z}.
FT   HELIX        51     54       {ECO:0000244|PDB:3O5Z}.
FT   STRAND       56     61       {ECO:0000244|PDB:3O5Z}.
FT   TURN         62     64       {ECO:0000244|PDB:3O5Z}.
FT   STRAND       67     71       {ECO:0000244|PDB:3O5Z}.
FT   HELIX        72     74       {ECO:0000244|PDB:3O5Z}.
FT   STRAND       75     81       {ECO:0000244|PDB:3O5Z}.
FT   HELIX       114    117       {ECO:0000244|PDB:2XS6}.
FT   HELIX       126    138       {ECO:0000244|PDB:2XS6}.
FT   HELIX       144    146       {ECO:0000244|PDB:2XS6}.
FT   HELIX       162    164       {ECO:0000244|PDB:2XS6}.
FT   HELIX       167    180       {ECO:0000244|PDB:2XS6}.
FT   STRAND      181    183       {ECO:0000244|PDB:2XS6}.
FT   HELIX       188    199       {ECO:0000244|PDB:2XS6}.
FT   HELIX       206    209       {ECO:0000244|PDB:2XS6}.
FT   TURN        211    213       {ECO:0000244|PDB:2XS6}.
FT   HELIX       216    235       {ECO:0000244|PDB:2XS6}.
FT   HELIX       239    255       {ECO:0000244|PDB:2XS6}.
FT   HELIX       279    293       {ECO:0000244|PDB:2XS6}.
FT   HELIX       439    512       {ECO:0000244|PDB:3MTT}.
FT   HELIX       515    583       {ECO:0000244|PDB:3MTT}.
FT   HELIX       588    594       {ECO:0000244|PDB:3MTT}.
SQ   SEQUENCE   728 AA;  81545 MW;  ADAC3E4B61F3F44A CRC64;
     MAGPEGFQYR ALYPFRRERP EDLELLPGDV LVVSRAALQA LGVAEGGERC PQSVGWMPGL
     NERTRQRGDF PGTYVEFLGP VALARPGPRP RGPRPLPARP RDGAPEPGLT LPDLPEQFSP
     PDVAPPLLVK LVEAIERTGL DSESHYRPEL PAPRTDWSLS DVDQWDTAAL ADGIKSFLLA
     LPAPLVTPEA SAEARRALRE AAGPVGPALE PPTLPLHRAL TLRFLLQHLG RVASRAPALG
     PAVRALGATF GPLLLRAPPP PSSPPPGGAP DGSEPSPDFP ALLVEKLLQE HLEEQEVAPP
     ALPPKPPKAK PASTVLANGG SPPSLQDAEW YWGDISREEV NEKLRDTPDG TFLVRDASSK
     IQGEYTLTLR KGGNNKLIKV FHRDGHYGFS EPLTFCSVVD LINHYRHESL AQYNAKLDTR
     LLYPVSKYQQ DQIVKEDSVE AVGAQLKVYH QQYQDKSREY DQLYEEYTRT SQELQMKRTA
     IEAFNETIKI FEEQGQTQEK CSKEYLERFR REGNEKEMQR ILLNSERLKS RIAEIHESRT
     KLEQQLRAQA SDNREIDKRM NSLKPDLMQL RKIRDQYLVW LTQKGARQKK INEWLGIKNE
     TEDQYALMED EDDLPHHEER TWYVGKINRT QAEEMLSGKR DGTFLIRESS QRGCYACSVV
     VDGDTKHCVI YRTATGFGFA EPYNLYGSLK ELVLHYQHAS LVQHNDALTV TLAHPVRAPG
     PGPPPAAR
//
